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CASE PRESENTATION
A 69-year-old white male attorney was referred three years ago because
of progressive hypertension and declining renal function. He had smoked
two packs of cigarettes daily for the past 55 years. Modest hypertension
had been successfully treated with a thiazide diuretic for several years. At
age 51, an 8 cm abdominal aortic aneurysm was resected. His blood
pressure had risen 4 years ago to levels between 170/108 mm Hg and
205/110 mm Hg despite increased medications: pindolol, 5 mg twice daily;
prazosin, 5 mg twice daily; and indapamide, 2.5 mg daily. His serum
creatinine rose from 0.9 mg/dl at age 52 to 2.0 mg/dl at age 66. He was
aware of several episodes of confusion, which had been attributed to
lacunar strokes, but he remained able to work and function normally. He
had no history of myocardial infarction or angina; an electrocardiogram
disclosed left-ventricular hypertrophy. Hyperlipidemia had been treated
with lovastatin, cholestyramine, and niacin. His medical history included
resection of cancer of the penis and recently detected adenocarcinoma of
the prostate, for which radiation therapy had been planned.
Physical examination revealed an alert and functional man. His blood
pressure was 205/108 mm Hg; and the pulse was 75 beats/min. The weight
was 195 lbs, the height, 69 inches. Ophthalmic examination demonstrated
grade II retinopathy. No carotid bruits were heard. Cardiac examination
revealed a fourth heart sound. An abdominal scar was present, a result of
the abdominal aneurysm surgery. Epigastric and abdominal bruits were
detected in every quadrant. Pulses in the lower extremities were dimin-
ished. Pitting edema was present at the ankles.
Laboratory data disclosed: hematocrit, 42.8; hemoglobin, 14.9 g/dl;
serum creatinine, 2.0 mg/dl; sodium, 140 mEq/liter; potassium, 3.8 mEq/
liter; uric acid, 8.4 mg/dl; albumin, 4.2 g/dl; calcium, 9.3 g/dl; PO4, 3.1
mg/dl; and glucose, 122 mg/dl. Total cholesterol was 180 mg/dl; triglycer-
ides, 122 mg/dl; HDL, 38 mg/dl. Urinalysis disclosed 11 proteinuria. A
chest radiograph demonstrated an elevated right hemidiaphram, scattered
fibrosis, and a tortuous aorta. An electrocardiogram showed left-ventric-
ular hypertrophy with strain pattern and was unchanged from previous
tracings.
A renal angiogram demonstrated single renal arteries bilaterally with
high-grade stenoses at their origins (Fig. 1). Severe atheromatous changes
were present in the abdominal aorta, as were postoperative changes of a
straight graft repair of the infrarenal abdominal aorta. Bilateral common
iliac artery aneurysms were found. High-grade stenosis was present at the
origin of the celiac artery. Renal-vein renin values were as follows: right,
13.2 ng AI/ml/hr; left, 10.0 ng/AI/ml/hr; and inferior vena cava, 6.7 ng
AI/ml/hr.
Over the three years since he was originally seen, the antihypertensive
regimen has comprised indapamide, 2.5 mg daily; pindolol, 5 mg twice
daily; and hydralazine, 25 mg, and prazosin, 5 mg each three times daily.
He continued to take cholestyramine; lovastatin, 40 mg qd; niacin, 1000
mg; glyburide, 1.25 mg daily, was added a year or so ago. Home blood
pressure readings ranged between 140/75 mm Hg and 155/80 mm Hg.
Ambulatory blood pressure readings indicated average values of 149/83
mm Hg. Serum creatinine was 2.2 mg/dl; creatinine clearance, 38 ml/min.
Amaurosis fugax developed at age 69, which carotid endarterectomy
corrected without complications. He continued to smoke. He completed
radiation therapy for carcinoma of the prostate, for which he now has no
evidence of disease. A magnetic resonance angiogram (MRA) with
gadolinium contrast medium was performed to determine progression (or
not) of the vascular lesions (Fig. 2). Aneurysmal dilation above the
previous graft remained visible, but no progression in the renal artery
lesions per se could be seen.
DISCUSSION
DR. STEPHEN C. TEXTOR (Consultant, Division of Hypertension,
Mayo Clinic; and Associate Professor of Medicine, Mayo Medical
School, Rochester, Minnesota): The patient presented here illus-
trates several vexing questions raised regularly to nephrologists
and internists by patients with atherosclerotic vascular disease. At
the initial referral, this patient’s hypertension was accelerating,
almost certainly related to renal artery stenosis. Renal-vein-renin
determinations suggested more severe stenosis to the right kidney,
but renin values were elevated on both sides, and stenosis was
present bilaterally. This patient faced the risk of bilateral progres-
sion and a continued decline in renal function; some have termed
this condition “ischemic nephropathy” [1–3]. Renal revasculariza-
tion can improve blood pressure control and sometimes forestall
progressive vascular compromise to the kidneys, but the hazards
of surgical revascularization were substantial in this patient; he
had extensive aortic disease, previous abdominal aortic recon-
struction and, later, symptomatic carotid artery disease. The
initial decision regarding management of his renovascular disease
was complicated further by newly identified prostatic cancer. The
clinical judgment regarding renal revascularization therefore re-
flected a complex balance of risks and benefits.
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Fig. 1. Contrast aortogram at age 66 (A)
and selective right renal artery injection (B).
The previous aortic graft is visible in the
infrarenal aorta. Aneurysmal dilation of the
aorta above the graft can be seen, from
which the renal arteries arise. A high-grade
stenosis with post-stenotic dilation of the
right renal artery is present. Moderate
stenosis of the left renal artery is present.
Renal vein renin measurements demonstrated
bilateral release of renin, although more
pronounced from the right (see text). Arrows
indicate vessels with proximal stenoses.
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Fig. 2. Magnetic resonance angiogram with gadolinium contrast obtained three years later. Aortic dilation above the previous graft is still visible, and
the stenotic lesion in the right kidney has not changed appreciably during this interval. Sagittal reconstruction of the image demonstrates the origin of
the renal arteries, with severe obstruction on the right and only modest narrowing of the left, although it arises from the aneurysmal segment.
My objective today is to examine the changing characteristics of
patients diagnosed with atherosclerotic renal disease and renal
failure, identify the risks of developing progressive renal failure
attributable to renal vascular disease, and to consider the risks and
clinical outcomes of surgical revascularization in these patients.
As a practical matter, the decision about whether to proceed with
renal revascularization hinges on an integrated assessment of
these factors for each patient, combined with other considerations
regarding general health and likely survival without vascular
intervention.
Let me state from the outset that I believe that the value of
renal revascularization remains controversial. Advances in vascu-
lar imaging, interventional radiology, and surgical revasculariza-
tion have produced champions of each technology; each camp
relies on data fraught with patient selection and publication biases
that obscure general application. The clinical issues have been
addressed from different points of view, for example, those of
interventional radiologists who identify and correct vascular ste-
noses (without having much of a role in direct management of the
patient), nephrologists who must manage end-stage renal disease
and who are concerned that renovascular disease plays a causal
role, and internists who must manage resistant hypertension and
early renal failure. These differences in perspective sometimes
hinder formulation of a cohesive understanding of progressive
atherosclerotic renal artery disease. How best to recognize critical
renal arterial disease in a timely manner and how to recognize
when surgical intervention offers genuine benefit remain the
major clinical challenges facing the physician responsible for each
patient.
Effects of aging. Mortality rates for coronary artery disease and
stroke have fallen steadily for the last 25 years [4]. As a result,
patients above age 65 now represent a rapidly growing segment of
the U.S. population; this trend is expected to continue into the
next century [5]. Some researchers believe that reduced mortality
from acute coronary disease permits the gradual development of
critical, non-coronary atherosclerotic disease, including the ab-
dominal aorta and renal arteries. Their view is supported by the
recognition that atherosclerotic renal artery disease is becoming
more common in older patients. Several studies indicate that
abdominal aortic disease or renal artery stenosis, often unsus-
pected, is present in 15% to 23% of patients undergoing coronary
angiography [6, 7]. Renal arterial disease is present in 45% to 50%
of patients undergoing angiography for lower extremity peripheral
vascular disease [8, 9]. Together with Dr. Hallett, my colleagues
and I compared patients undergoing renal revascularization at
Mayo Clinic during two time periods: 1981–1993 and the decade
between 1970–1980. The average age at surgery increased sub-
stantially, as did the prevalence of associated comorbid condi-
tions, including diabetes, congestive heart failure, and cerebrovas-
cular disease [10]. This trend is common to many progressive
diseases of our aging population [5, 11]. Thus, patients with
potentially reversible, critical renal artery stenoses generally are
older and more complex medically now than ever before.
Medical therapy for renovascular hypertension. The impact of
new antihypertensive agents on the management of renovascular
hypertension has been profound. In the 1970s, antihypertensive
regimens were limited to sympatholytic agents such as methyl-
dopa, reserpine, and guanethidine, combined primarily with thi-
azide diuretics. Vasodilators used later included hydralazine and
minoxidil. These agents were remarkably effective in many pa-
tients, but they routinely produced onerous side effects. No agents
were available specifically to interrupt the renin-angiotensin sys-
tem. Most important, they failed to control hypertension in some
patients, who sometimes progressed to malignant hypertension
with loss of renal function. Presentation with accelerated hyper-
tension, including both grade III (retinal hemorrhages) and IV
(papilledema) retinopathy, was attributable to renovascular hy-
pertension in as many as 32% of patients in the 1970s, at least in
whites [12]. In the 1970s, even bilateral nephrectomy was used as
a lifesaving procedure to relieve malignant hypertension [13, 14].
Both angiotensin-converting-enzyme (ACE) inhibitors and cal-
cium-channel-blocking agents became widely available in the early
1980s. Hollenberg reviewed the impact of ACE inhibitors on
renovascular hypertension [15, 16]. Before the advent of this drug
class, medical treatment controlled blood pressure in fewer than
46% of patients (usually defined as blood pressure levels below
160/90 mm Hg) [16]. But the availability of ACE inhibitors
resulted in excellent blood pressure control in 82% to 95% of
patients in prospective series [17, 18]. Under some conditions,
ACE inhibitors can reduce glomerular filtration rate, particularly
in patients with renal artery stenosis [19, 20]. However, GFR does
not usually fall in patients with unilateral disease, even in those
with surgically proven renovascular hypertension [21]. Although
this phenomenon is well known [22], the fraction of patients with
even high-grade bilateral renal artery stenosis in whom renal
function significantly declines is on the order of 25% to 38% [21].
Calcium-channel-blocking agents, another potent group of agents,
have been remarkably well tolerated and effective, as compared to
medications used previously. Additional classes, including the
angiotensin-receptor-blocking agents (for example, losartan),
continue to expand therapeutic options. The concept of urgent,
bilateral nephrectomy as a therapeutic consideration for patients
with accelerated hypertension has virtually disappeared.
One rarely appreciated result of improved medical therapy is
that many patients with renovascular hypertension now are never
identified. Recent recommendations from the Joint National
Committee (JNC) of the National High Blood Pressure Educa-
tion Program argue for minimal laboratory investigation of pa-
tients whose blood pressure is well controlled and whose renal
function is stable [4]. As I will discuss momentarily, many patients
with identified renal artery stenosis can be managed satisfactorily
with current medical antihypertensive regimens.
Thus, renal revascularization for controlling or “curing” reno-
vascular hypertension is currently less pressing than a decade ago.
The patient under discussion today illustrates how medical ther-
apy can be used to satisfactorily control blood pressure. But some
interventionists are concerned that even though the blood pres-
sure may be controlled, loss of renal function still might progress.
A critical question thus is: what are the risks of progressive renal
artery stenosis and progressive renal failure as compared to the
risks of revascularization?
Progressive renal artery stenosis and renal failure. Atherosclerotic
disease of the renal arteries is a progressive disorder [23, 24].
Early studies identified progression to renal artery occlusion in
44% to 50% of patients followed for five years [25, 26]. Duplex
ultrasound studies indicate that 24% of stenotic lesions with more
than 60% luminal narrowing advance over fourteen months and
such vascular progression is associated with loss of renal volume
[27, 28]. Some clinicians have interpreted these data as mandating
early intervention, for example, angioplasty on any “significant”
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lesion [29, 30]. But we should keep in mind that the same data
indicate that more than one-half of patients do not progress
during the same interval. Whether similar rates of progression will
be encountered in the future, particularly with improved antihy-
pertensive therapy, decreased tobacco use, and more intensive
lipid reduction, is not certain [31]. But preliminary reports of
patients with known bilateral renal artery disease randomized to
either medical or surgical therapy indicate that rates of progres-
sion are less than a decade ago [32, 33].
As many as 15% of patients over age 50 who reach end-stage
renal disease (ESRD) have underlying atherosclerotic renal artery
stenosis without other primary renal disease [23, 24]. The concept
that critical renal underperfusion might account for their dialysis
requirement is supported by occasional reports of renal revascu-
larization that leads to recovery of sufficient renal function to
allow the patient to discontinue dialysis [35, 36]. Enthusiasm for
revascularization in patients with atherosclerotic disease must be
tempered, however, both by the risks and costs involved, and even
more importantly by major gaps in our understanding of which
patients are likely to recover renal function and benefit from
taking those risks.
Pathophysiology of “ischemic nephropathy.” A large body of
research regarding renal underperfusion leading to renovascular
hypertension dictates clinical practice. Reviews of this subject
have been presented elsewhere [37, 38]. Hypertension in patients
with renal artery stenosis is mediated by multiple effector mech-
anisms, including the renin-angiotensin system, sympathetic ner-
vous pathways, and alteration of the balance among nitric oxide,
eicosanoids, and other vasoactive systems [39, 40]. While impor-
tant questions remain, particularly regarding long-term adapta-
tion to vascular stenoses, the availability of animal models and
intense research activity have produced sufficient information to
allow us to rationally address renovascular hypertension in hu-
mans.
Unfortunately, substantive data related to the pathophysiology
of parenchymal renal failure during chronic underperfusion of the
kidney are much more limited [41, 42]. The importance of our
need to better understand this process cannot be overstated.
Recent reviews highlight potential mechanisms by which intermit-
tent, non-sustained regional underperfusion within the kidney
might alter cell polarity and structure, initiate cytokine release,
and activate interstitial fibrosis [43, 44]. Whole-organ measure-
ments of oxygen consumption suggest, however, that true “isch-
emia,” that is, a deficit of oxygen delivery, does not develop, even
in severely underperfused kidneys [45, 46]. In view of the kidney’s
large filtering function, it is vastly overperfused in terms of oxygen
delivered. Hence the term “ischemic nephropathy” carries as-
sumptions that have neither been tested nor confirmed. The
possibility of local intrarenal areas of true ischemic injury cannot
be excluded.
Figure 3 illustrates a general paradigm by which impaired renal
perfusion leads to interstitial fibrosis and renal failure. The details
of what cellular mechanisms induce irreversible parenchymal
injury in this condition remain to be fully elucidated. A central
element to this paradigm is that restoration of arterial perfusion
to the kidney beyond a critical stenosis can restore renal function.
Unfortunately, renal function does not recover uniformly. Under
some conditions, loss of renal function beyond a stenotic lesion
leads to irreversible parenchymal injury. Thus, understanding the
mechanisms by which renal failure occurs, or at least identifying
when renal function is no longer salvageable, likely will be
essential for the rational application of vascular restoration in
patients.
Outcomes of renal revascularization in azotemic patients. Several
investigators believe that preservation of renal function and
improvement in blood pressure control are indications for renal
revascularization [47, 48]. Results regarding blood pressure con-
trol should be considered separately from changes in renal
function. We have reviewed the experience at Mayo Clinic dating
back to 1970 regarding both angioplasty and surgical revascular-
ization [10, 49].
Does renal revascularization in fact return blood pressure to
normal levels? Initial attempts at both surgical bypass, and later
percutaneous transluminal renal angioplasty (PTRA), focused on
Fig. 3. Paradigm by which critical renal
artery stenosis can lead to irreversible renal
injury. Central to this discussion is the
concept that restoration of renal perfusion
may allow recovery or preservation of renal
function. At some point, however, these
changes become irreversible. The sequence of
events leading to irreversible change is poorly
understood.
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“cure” of hypertension. Considerable effort was directed toward
establishing that the renal artery stenotic lesions were responsible
for hypertension [37, 50]. Hence a series of functional studies
including side-to-side comparisons of renal function were devel-
oped. Most recently, side-to-side comparisons of renal vein renins
have been employed to identify the responsible “pressor” kidney
[51]. Such functional studies indeed provided support for surgical
intervention when strong lateralization was demonstrated [52–54].
Remarkably, several series suggested that even when renal vein
values did not lateralize, improved blood pressure control was
likely in more than one-half the cases [54, 55].
These “side-to-side” diagnostic studies are less commonly em-
ployed today because of three main reasons. (1) Improved blood
pressure control is rarely the foremost consideration for revascu-
larization. (2) The concept of “cure” in atherosclerotic renovas-
cular disease has been tempered. Renal revascularization reduces
but rarely eliminates the requirement for antihypertensive drug
therapy [56–58]. (3) Some improvement in blood pressure control
is evident even in patients without lateralizing renal vein renin
studies. Most patients with atherosclerotic disease have long-
standing hypertension, which remains even after the pressor
effects of an underperfused kidney are removed. Hence, the
number of medications falls, on average, from 2.6 to 1.4 antihy-
pertensive medications per patient, but rarely to zero [49, 58].
Reported cure rates for hypertension related to atherosclerotic
disease range from 13% to 55% of patients [58, 59]. In sum,
improved blood pressure control with less medication is a realistic
goal of renal revascularization.
Can revascularization restore renal function? The answer is yes,
but accurately predicting changes in renal function after either
surgical revascularization or renal angioplasty is among the most
difficult problems in this field. Although small series and isolated
cases demonstrate the possibility of excellent recovery of renal
function, such results are infrequent. Patients with nearly normal
renal function (usually defined as a serum creatinine concentra-
tion less than 1.5 mg/dl) have little long-term change in serum
creatinine after surgical revascularization or PTRA [47, 56, 59].
We evaluated the effects of renal revascularization in patients
with serum creatinine levels of 2.0 mg/dl or higher. The overall
results of 253 patients with atherosclerotic disease (out of 320
total patients with a variety of diseases) undergoing PTRA have
been published previously [49]. Of these 253, 44 were azotemic at
the time they underwent PTRA. Several features in our experi-
ence (shared by others) merit consideration [49]. Figure 4 illus-
trates changes in serum creatinine before and after PTRA both in
azotemic (n 5 44) and nonazotemic patients (n 5 209). Pre-
intervention serum creatinine values in azotemic subjects were
3.47 6 0.25 mg/dl and were 3.36 6 0.28 mg/dl at last followup
(NS). Group values, however, obscure the real clinical outcomes
in this situation. Figure 5 shows individual serum creatinine values
for the 44 azotemic patients. In our review of renal outcomes, we
divided patients into groups according to a clinically meaningful
change in renal function: Group A (fall in serum creatinine $ 1.0
mg/dl), Group B (change in serum creatinine , 1.0 mg/dl), and
Group C (rise in serum creatinine $ 1.0 mg/dl). Panel A depicts
12 patients who had major improvements in serum creatinine
(4.82 6 0.60 mg/dl to 2.42 6 0.34 mg/dl), Panel B shows the 23
patients who had no change (2.90 6 0.25 mg/dl to 2.91 6 0.32
mg/dl), and Group C represents the 9 who had a major loss of
renal function (3.09 6 0.24 mg/dl to 5.73 6 0.44 mg/dl). As the
figure indicates, changes in renal function were not always evident
immediately after PTRA, but were evident at later followup
review (mean followup, 21 months). The 9 patients with deterio-
rating renal function had poor clinical results: 8 of the 9 required
dialytic support or died within one year after the procedure. No
technical features (that is, patency rates or success at dilation)
were evident to account for differences among the groups. In
some cases, embolic changes evident in other vascular beds,
including the feet and skin, suggested that atheroembolic disease
was responsible for renal deterioration in many of these individ-
uals.
A review of the procedures and results of 304 azotemic patients
undergoing surgical renal revascularization during the same time
interval (1980–1993) has been published from our institution.
Remarkably, the average serum creatinine values and the propor-
tions falling into each outcome category were similar to those who
had undergone PTRA [10, 49]. Among 304 patients with serum
creatinine levels above 2.0 mg/dl, 28% of patients (84 of 304) had
a meaningful improvement in renal function, defined as a reduc-
tion in serum creatinine level of 1.0 mg/dl. Most (52.6%, or 106 of
304) had no change, defined as a change in serum creatinine of ,
1.0 mg/dl. Creatinine levels rose more than 1.0 mg/dl in a
substantial percentage (19.7%, or 60 of 304) after surgical revas-
cularization; this increase reflected a clinically important loss of
renal function.
Regardless of the means of revascularization, long-term renal
function can significantly improve or it can deteriorate. Even
authors who favor PTRA differentiate between “technical suc-
cess,” successful establishment of a patent renal artery lumen, and
“clinical success,” that is, improved renal function [47]. The two
results do not necessarily co-exist. Hence, studies invariably
contain a group in which “technical success” is accompanied by
clinical deterioration. In several series of surgical patients, renal
functional outcomes in atherosclerotic patients were mixed, and
serum creatinine values generally did not change [57, 58, 60–62].
Most series report renal function as “improved” or “stable,” in
effect, comparable to our groups (Fig. 5 A and B). If renal
Fig. 4. Serum creatinine levels before (“pre”), immediately after
(“post”), and at last followup (mean, 25 months) in 253 patients with
atherosclerotic disease undergoing percutaneous transluminal renal an-
gioplasty (PTRA). Symbols are: (p) creatinine $ 2.0, N 5 44; ( )
creatinine , 2.0, N 5 209). Group mean values demonstrated no change
overall, either in patients with pre-existing renal failure or patients with
normal renal function.
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Fig. 5. Individual values of serum creatinine before and after percuta-
neous transluminal renal angioplasty (PTRA) in 44 patients with
azotemia (creatinine > 2.0 mg/dl). Panels A, B, and C are defined by
changes in creatinine after PTRA. (A) Patients (N 5 12) with a major
improvement in renal function, reflected by a fall from 4.8 6 0.6 to 2.4 6
0.3 mg/dl. While the majority (N 5 23) had no significant change in
creatinine as shown in (B), others had a major loss of renal function,
reflected by a rise in creatinine from 3.1 6 0.2 to 5.7 6 0.4 mg/dl (C; N 5
9). Most of these patients progressed to require dialysis or died within the
subsequent 12 months. Abbreviation LFU is last followup.
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function improves in some and yet overall mean values do not
change, clearly there are patients whose renal function deterio-
rates, although this point is often not addressed directly.
Does renal functional change affect overall patient outcome?
As one would anticipate, the answer is yes. Patients with a major
loss (defined as $ 1.0 mg/dl) of renal function (between 20% and
25% of patients in most series) are likely to need dialytic support,
both acutely and chronically. Chaikof and colleagues emphasized
the importance of improved renal function when they recognized
that long-term patient survival was closely related to glomerular
filtration rate soon after renal revascularization [61].
Deterioration of renal function after vascular intervention is
not rare. The exact basis of the loss of renal function is not clear,
although atheroembolic renal disease undoubtedly plays a role.
Thadhani et al reviewed the clinical course of 52 patients with
histologically proven atheroembolic disease following angiogra-
phy and found gradual progression to renal failure; that is, 23 of
52 patients (44%) required dialysis within 6 months [63]. Never-
theless our limited understanding of the precise cause of paren-
chymal renal injury beyond renal artery stenosis is a major
handicap in this regard. We cannot exclude the possibility that
sudden restoration of perfusion pressure, which perhaps gener-
ates toxic free radicals or oxygenated species, exposes the kidney
to further injury after revascularization. Hence, we should care-
fully weigh the possible risks and benefits of revascularization.
Given all these results, what pre-intervention data best assist us
in predicting the results of renal revascularization? Our experi-
ence suggests that distinguishing between “early survival” (within
30 days of surgical revascularization) and “late” survival (beyond
30 days, assuming survival to that point) is helpful. As expected,
early surgical risk is most closely related to the magnitude of the
procedure (that is, whether concurrent aortic reconstruction is
attempted) and to the presence of active cardiovascular disease,
that is, congestive heart failure, angina, or cerebrovascular dis-
ease. In our series of 304 patients, early survival (30 days or less)
did not depend on pre-operative levels of renal function, age, or
other clinical variables [64].
Late survival (beyond 30 days) depended on other factors.
Pre-operative level of renal function (as defined by 1/creatinine),
age above 70 years, and the presence (not repair) of an aortic
aneurysm independently predicted shortened survival. These data
are consistent with other reports suggesting that patients with
more advanced levels of renal failure rarely have major improve-
ments in function [24, 36, 62, 65]. The presence of diabetes did not
independently predict shortened survival, but it did independently
relate to duration of hospitalization and costs of the procedure
[66]. We used a Cox proportional hazards model to predict renal
functional outcome using a late serum creatinine above 4.0 mg/dl
as an end point. In this instance, the strongest predictors of
deteriorating renal function were (1) pre-operative serum creati-
nine, (2) male gender, (3) aortic repair, and (4) an inverse
relationship to congestive heart failure [66].
An integrated approach to the patient with atherosclerotic renal
artery disease. How do the internist and nephrologist apply this
information to patients such as the man presented today? My
recommendation is that we treat such patients individually; close
evaluation should monitor changes in renal vascular lesions, renal
function, and blood pressure. If disease progression is evident and
other, patient-specific, risk factors favor long-term survival, then
renal revascularization should be considered. Our data and those
of others favor initiating this process before advanced renal
dysfunction is evident. Hence, we believe that the “window of
opportunity” is defined by serum creatinine levels between ap-
proximately 1.5 mg/dl and 3.0 mg/dl for most surgical revascular-
ization. Our interpretation recognizes that waiting for advanced
renal failure to develop diminishes the likelihood that renal
function will improve after revascularization. Several series sug-
gest that serum creatinine levels above approximately 3.0 mg/dl
are associated both with poor renal and patient outcomes. These
data also must be considered in light of relatively poor survival
with hemodialysis in such patients [23].
Conversely, patients with nearly normal renal function and
well-controlled blood pressure gain relatively little more from
renal revascularization. Cure rates are limited in patients with
atherosclerotic disease, so continued antihypertensive therapy
likely is necessary. Withholding either PTRA or surgery avoids
exposing these patients to the immediate risks and costs of these
procedures, which may never be needed. Results of several recent
prospective series support this impression. Preliminary results
from Scotland indicate no major benefit in renal function in
patients randomized to PTRA as compared to medical therapy
[32].
Patients with atherosclerotic renal artery disease continue to
present major challenges to internists and nephrologists. This is
an expanding problem, as the U.S. population ages and renal
artery lesions appear in older patients with more widespread
problems and limitations. There is a pressing need to more closely
examine prospectively the role of vascular disease in producing
chronic renal failure. Until these studies are available, managing
such patients requires an intensely individualized approach, as I
have tried to outline today.
QUESTIONS AND ANSWERS
DR. JOHN T. HARRINGTON (Dean, Tufts University School of
Medicine, Boston, Massachusetts): Steve, you told us that serum
creatinine fell from about 4 mg/dl to 2 mg/dl in 28% of the
patients operated on in your series. Could you propose a way that
would currently identify that quota of the patient population?
Second, can you speculate on what you’d like to look at to try to
better identify that 27% in the future?
DR. TEXTOR: The simple answer is “no.” We have no specific
way of identifying patients whose renal function will improve after
revascularization. In 1985, we reported in the Annals of Internal
Medicine that we had used nitroprusside to reduce blood pressure
in a stepwise fashion. We were able to identify a “critical perfusion
pressure” at which blood flow to the kidneys fell sharply. Those
patients regained blood flow after we revascularized even one
kidney. That method constitutes a “stress test” to the kidney and
does identify critical stenoses, but it is technically difficult. There
are a few clinical predictors, although they are weak. A rapid rise
in the serum creatinine concentration immediately before clinical
diagnosis of renal artery stenosis may be a positive sign for
recovery of renal function. In a multivariate analysis, renal
function after revascularization improved more in patients with
congestive heart failure than in others [67]. The reason is not
clear; we can only suppose that part of the renal impairment is due
to pre-renal azotemia and that some of the benefits of renal
revascularization also reflect improved cardiac function.
We are undertaking studies with the goal of predicting clinical
responses. In renal biopsy specimens examined at the time of
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surgical revascularization, the degree of interstitial fibrosis tends
to be the best predictor of functional recovery, as with most other
renal diseases. What governs interstitial fibrosis during post-
stenotic underperfusion of the kidney is not clear, but we suppose
that multiple factors participate, including angiotensin II, oxida-
tive stress, and stimulation of cytokines.
DR. NICOLAOS E. MADIAS (Chief, Division of Nephrology, New
England Medical Center, Boston, Massachusetts): You compared
patients who were treated with surgery at Mayo Clinic in the 1970s
and early 1980s with those who were treated in the late 1980s and
early 1990s. One major difference between the two groups must
be the variable use of ACE inhibitors. The issue is, when you
tabulated renal function at baseline or at followup, was a compo-
nent of functional azotemia present due to ACE inhibition? How
did you deal with this phenomenon either before or after the
intervention?
DR. TEXTOR: That is an important question. We did construct a
database including medications before and after surgery. Let me
emphasize that our patient group all had serum creatinine lev-
els $ 2.0 mg/dl. With the recognition that ACE inhibitors could
produce acute functional renal insufficiency, the prevailing con-
cept in the 1980s was that these agents should be avoided in
patients with renal insufficiency. As a result, remarkably few—
approximately 17%—were taking ACE inhibitors before surgery.
Thus, the use of ACE inhibitors did not appear to have been an
important factor in these patients. It is possible that some patients
had earlier exposure to ACE inhibitors and perhaps developed a
temporary loss of GFR that prompted withdrawal of the drugs. I
cannot tell much about that from our data.
DR. MADIAS: As you indicated, the reason that we opt for
revascularization is the concern that progressive renal dysfunction
will occur. Yet, as you noted, a number of patients don’t experi-
ence this problem. In my own practice, I have been impressed by
the fact that a sizeable number of patients I have followed for a
long time, who had severe bilateral renovascular stenoses or renal
artery stenosis in a solitary kidney and had either refused or failed
intervention, actually maintain remarkably stable renal function.
Could you please expand on our knowledge about the natural
history of untreated advanced renovascular disease, particularly
on existing controlled, prospective data?
DR. TEXTOR: The natural history of atherosclerotic renal artery
disease is somewhat controversial. In the early 1980s, Novick and
associates emphasized revascularization’s potential for preserving
renal function [see Ref. 24]. This possibility seemed especially
important in view of several retrospective series suggesting that
between 40% and 50% of lesions progressed over relatively short
time periods [25, 26]. Few prospective data are available, however,
particularly recently, when more attention has been paid to
vascular risk factor intervention, such as lipid reduction and
withdrawal of smoking. To their credit, the Cleveland Clinic group
has enrolled patients in a prospective, randomized study of
progressive renal artery disease. The results of this trial have not
yet been published, but preliminary discussion with the investiga-
tors indicates that current rates of progression have not been as
high as predicted. These data are consistent with other recent
trials comparing renal angioplasty with medical therapy and with
other recent investigations using Doppler ultrasound studies in
atherosclerotic disease [32, 68, 69]. All these data suggest that
rates of disease progression to critical levels are less than earlier
studies suggested, more on the order of 20% to 25% over 3 years.
DR. GEETHA NARAYAN (Division of Nephrology, St. Elizabeth’s
Hospital, Brighton, Massachusetts): I have two questions. What has
been the experience at your institute with respect to angioplasty
with and without stents? Also, could you comment on your
incidence of complications, especially atheroembolic, with respect
to these procedures? To expand on that question, is there a
correlation between these complications and the degree of aortic
disease as we saw in this gentleman? Should the magnitude of the
aortic disease be a determinant of who should not subjected to the
procedure?
DR. TEXTOR: We are entering an era of stents. Our own
experience does support the use of stents in some situations,
particularly with ostial lesions that fail angioplasty. Our interven-
tional radiologists are conservative in this regard, in part because
currently few long-term data exist regarding outcomes, although a
recent paper from Germany does support the relative safety of
stents [70]. Once stented, however, the vessel is never the same. If
surgical intervention is needed later, the option of repairing a
stented vessel is limited. Occasionally, stents have migrated out of
position and protrude into the aorta. I am confident that most of
these problems will be overcome as technology advances. But let
me emphasize that clinical results related to blood pressure and
changes in renal function—both favorable and unfavorable—are
not related directly to which method of revascularization is
chosen. Furthermore, none of these procedures avoids the risk of
atheroembolic events.
DR. MARK E. WILLIAMS (Division of Nephrology, New England
Deaconess Hospital, Boston, Massachusetts): Getting back to the
role of ACE inhibitors, both diagnostically and therapeutically, do
you think the behavior of renal function in response to acute ACE
inhibitor therapy provides any predictive information about the
likelihood of long-term benefit with revascularization?
DR. TEXTOR: That is a good question. It reflects the hope in the
early 1980s that the blood pressure response to ACE inhibitors
would predict surgical outcomes. Several published series ad-
dressed this point by administering ACE inhibitors to patients
with known renal artery disease. In the series by Jackson et al, the
incidence of acute renal dysfunction (defined as a tripling of
serum creatinine) was 38% in patients with bilateral disease and
0% in patients with unilateral disease [71]. This result can be
interpreted several ways, but the study makes the point that in at
least 60% of patients with bilateral renal artery stenosis, renal
function did not worsen despite ACE inhibition. I know of few
data using ACE inhibitors that predict general response to renal
revascularization, but observation of serious renal deterioration
certainly raises the clinical likelihood of high-grade stenosis to the
entire functional renal mass. Failure to detect such a decrement,
however, does not exclude bilateral disease.
DR. WILLIAMS: Could you speculate about long-term therapy
with ACE inhibitors in renovascular disease in its milder forms:
do you think they are likely to be particularly beneficial or
nefarious?
DR. TEXTOR: That is a critical question, of course, particularly
with the broadening indications for the administration of ACE
inhibitors, as in patients with congestive cardiac failure. Some
authors take the position that administration of ACE inhibitors to
patients with renal artery stenosis leads to an irreversible fall in
GFR in the affected kidney, thereby constituting a “medical
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nephrectomy” [72]. I disagree with this interpretation. The likeli-
hood of excellent blood pressure control without clinically impor-
tant deterioration of renal function in patients with renal artery
stenosis has been excellent [16, 17]. Several experimental studies
suggest that functional deterioration of GFR attributable to ACE
inhibitors can be reversed so long as blood flow remains adequate;
we have reviewed this topic [22]. Of course, severe occlusive
vascular disease leading to impaired blood flow beyond a critical
point can lead to tissue underperfusion and permanent thrombo-
sis. In general, the notion that ACE inhibitors pose a particular
hazard in this setting has been overstated. A reassuring observa-
tion in this regard is the remarkable success in administering ACE
inhibitors to patients with advanced left-ventricular dysfunction,
as in the CONSENSUS and SAVE trials. Such patients have a
relatively high frequency of underlying, often unsuspected, renal
artery stenosis [7]. Despite this condition and the fact that such
patients may be prerenal, relatively hypotensive, and treated with
diuretics, the incidence of significant renal functional deteriora-
tion is remarkably low.
DR. JAMES STROM (Division of Nephrology, St. Elizabeth’s Hos-
pital): With the large experience that you’ve had with diagnostic
and selective arteriography, can you comment on the frequency of
hemodynamically significant renovascular disease versus arterio-
lar nephrosclerosis as the cause of gradually progressive chronic
renal failure? Should we approach both disorders conservatively
and not investigate at all?
DR. TEXTOR: How often slowly progressive renal failure repre-
sents large-vessel arterial stenosis is not known precisely. We have
prospectively studied patients who, based on clinical risk factors
and an asymmetric preliminary study, for example, abnormal
captopril renogram or differential renal size by KUB or ultra-
sound, are considered at high risk for underlying renal arterial
stenosis [73]. Remarkably, the incidence of renal artery stenosis
defined by subsequent angiography rarely exceeds 55%. Hence,
despite high clinical suspicion, a substantial portion of patients
have normal angiograms and abnormal renal function apparently
attributable to small-vessel disease or other causes. I believe that
our observations reflect many others’ experience.
DR. RICHARD KOPELMAN (Division of General Internal Medicine,
New England Medical Center): I have two questions. When
confronted with a patient whom you’ve decided to revascularize,
how do you decide between surgery and angioplasty? My second
question is: In the patient whom you’ve decided to follow medi-
cally, what parameters do you follow?
DR. TEXTOR: Those are practical questions. First, few studies
have systematically compared renal angioplasty versus surgery for
complex disease. A single Scandinavian study found similar
efficacy for both therapies in unilateral disease, although the
recurrence rate and need for further procedures was higher in
patients subjected to PTRA [74]. Most institutions depend on
local expertise in making such judgments. At our institution, we
feel fortunate to have excellent interventional radiology and
vascular surgery, which we view as complementary approaches.
Angioplasty is generally good and becoming better, but I am
concerned about the long-term durability of revascularization by
this means. Conversely, surgical revascularization poses consider-
able immediate expense and some risk despite its proven long-
term efficacy.
Regarding followup during medical therapy, we currently utilize
the parameters that would affect our management: careful assess-
ment of blood pressure control and renal function. If these two
variables are stable, no further studies are necessary.
DR. ANDREW S. LEVEY (Division of Nephrology, New England
Medical Center): I want to ask you more about atherosclerotic
renal vascular disease as a predictor of progressive renal failure.
Not only are there few prospective studies, but most of the
retrospective studies aren’t very good. The definition of the
patients is always altered by selection, which can’t be completely
explained. Even the retrospective studies don’t explain this dis-
ease. Rarely would we operate on people for control of blood
pressure. What we really need to think about is preventing renal
failure. I don’t mind if the patient has a serum creatinine level of
2 or 3 mg/dl so long as they can stay off dialysis and out of heart
failure. Are these noninvasive tests, such as the duplex sonogram
or MRA with gadolinium, sensitive enough to detect renal
lesions? Have studies been conducted to determine renal vascular
disease in a dialysis population, or alternatively in patients with
renal insufficiency, for example, patients with a serum creatinine
level of 3 mg/dl or more?
DR. TEXTOR: How best to identify patients with occult renal
artery stenosis is not known. Some instititions have developed
particular expertise with Doppler ultrasound and recommend
screening patients with advanced renal disease using that method
[75, 76]. Most other institutions have not achieved a high level of
confidence with this method. Our own sonographers still report
failure rates in as many as 20% of patients studied. Magnetic
resonance angiography is improving rapidly, particularly with the
use of nontoxic contrast media. Perhaps this technique will
improve our ability to detect such lesions.
Let me offer another caveat. Identifying a vascular lesion in a
patient with renal failure does not assure the clinician that this
lesion is responsible for the patient’s declining renal function. Nor
does it predict whether a patient will recover renal function after
revascularization. How to determine the latter needs considerable
further study.
DR. DAVID CAHAN (Chief of Nephrology, Faulkner Hospital,
Boston): Could you comment on age as an independent risk factor
for renal revascularization? In community practice, nephrologists
often encounter suspected renal vascular disease in patients well
into their 70s and 80s. Second, what is the utility of a simple test
such as ultrasonography in determining “how small is too small”
a kidney to revascularize?
DR. TEXTOR: Age is an important consideration. Impressive
advances in surgical technique and peri-operative support ser-
vices, including anesthesia and intensive care, mean that most
people can survive even complex surgical procedures. Of course,
reported series often include subjective screening and patient
selection biases that cannot be measured precisely. Age is an
important predictor of long-term survival, however, and the net
benefit from performing surgical procedures decreases as a result
of competing risks from other age-related diseases [77]. Most of
us realize this intuitively, although articulating this with our
patients and their families is often difficult.
Regarding identifying kidneys beyond salvage, many authors
have offered renal size as a possibility, arguing that radiographic
size less than 8 cm (based on a film of the abdomen; ultrasound
length would be smaller) means little chance of recovery. But
many exceptions exist, and we need more precise methods of
identifying kidneys worth revascularizing.
DR. RONALD PERRONE (Division of Nephrology, New England
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Medical Center): I was intrigued by your initial comment that one
of the patient syndromes that stimulates you to think about renal
artery disease is that of recurrent flash pulmonary edema. It
reminds me of a patient whose unstable angina was cured with
renal angioplasty. Do you think there are mechanisms other than
controlling hypertension or improving renal function and ulti-
mately volume balance that result from successful renal artery
repair?
DR. TEXTOR: Whether relieving renal artery stenosis affects
other vascular and cardiac events is an interesting question.
Studies using experimental models indicate that clamping the
renal artery quickly produces a broad range of neurohormonal
response [78, 79]. It activates the systemic renin-angiotensin
system and induces major increases of sympathetic nerve activity
and endothelium-dependent vasoactive materials, such as endo-
thelin. All these changes have widespread effects, including the
possibility of increasing coronary vascular tone. The exact means
by which these mechanisms magnify each other are not under-
stood. As you suggest, relief of critical renal artery stenosis in
patients with congestive heart failure can improve symptoms
beyond levels that can be explained by only improved renal
function and sodium balance.
DR. ANDREW KING (Division of Nephrology, New England Med-
ical Center): One of the points you made was that hypertension
due to renal artery stenosis is much more amenable to treatment
that is renal failure on that basis. You indicate several measures
that might contribute to the improved outcome of these patients.
Can you focus in on lipid metabolism? With the advent of an array
of lipid-reducing substances, and with the increasing recognition
that some atherosclerotic lesions in the coronary vascular bed can
regress with very aggressive control of lipid abnormalities, do you
think that similar results might be observed in the renal vascula-
ture? Are there any data to support that?
DR. TEXTOR: Let’s look at the lipid question in two parts. First,
is it possible that vigorous reduction of various lipid risk factors
will produce regression of vascular stenoses in the kidney? Such
regression has been observed in other vascular beds [80], and I see
no reason why this also should not occur in the kidney. Second, is
it possible that lipid-reducing therapy has other effects on the
kidney? It is possible that the myriad other effects of lipid
reduction via “statin”-class drugs, the HMG-CoA-reductase in-
hibitors, might affect the kidneys in positive ways other than
causing regression of large-vessel stenotic lesions. There is a
growing literature regarding the effects of lipids on accelerating
the progression of primary renal disease, of course.
DR. STROM: Might it be that a subgroup of patients that benefits
from renal revascularization is “hidden” by other subgroups that
cannot benefit due to irreversible glomerular sclerosis or that
suffer deterioration due to cholesterol embolism or technical
complications?
DR. TEXTOR: That is a fair question. Most surgical and angio-
plasty series offer some verification of technical success (or lack of
obvious technical failure) before considering the procedure a
failure. Cholesterol emboli may be more common than appreci-
ated and are difficult to diagnose. Certainly patients with uniden-
tified atheroemboli represent a “hidden” group of patients who
might have benefited. The possibility that rapid restoration of
renal perfusion to previously underperfused kidneys magnifies
oxidative stress and results in formation of toxic free radicals [81]
or another mechanism of injury cannot be excluded, of course.
Both of these possibilities need further exploration.
DR. MADIAS: I’d like to return to Dr. Williams’ concern
regarding the long-term safety of ACE inhibitors for renovascular
disease. The beneficial effects of ACE inhibitors on the cardio-
vascular system are undeniable. As you pointed out, when patients
with high-grade renovascular stenoses discontinue taking ACE
inhibitors, renal function usually recovers. When renal function
does not return to baseline, one can postulate that the underlying
renovascular disease has progressed. Nonetheless, some experi-
mental observations suggest that ACE inhibitors hasten ischemic
atrophy of the kidney behind a renovascular stenosis [82, 83].
Could you please comment further on this issue?
DR. TEXTOR: Several mechanisms contribute to the loss of renal
function beyond a stenotic lesion, and many of these are not
understood. We studied a model in the rat using an aortic
coarctation placed between the renal arteries [46, 84]. This
approach offers the advantage of allowing precise measurement
of post-stenotic arterial pressures. If one rapidly and drastically
reduces post-stenotic pressures, the kidney stops functioning and
undergoes necrosis and atrophy, regardless of additional medica-
tions. Some studies, such as those you mentioned, have adminis-
tered ACE inhibitors to animals with severe renal arterial stenosis
and demonstrated cortical necrosis associated with reduced blood
flow [82, 83]. Other studies, including our own, demonstrate that
ACE inhibition sufficient to reduce GFR without further impair-
ing blood flow to the kidney is tolerated without permanent renal
injury. Glomerular volume falls, but both structure and function
recover after removal of the arterial clip or the ACE inhibitors
[46, 85].
The predominant effect of ACE inhibition in humans with
various stages of renal artery stenosis is not known. Perhaps ACE
inhibition reduces the work of filtration and solute reabsorption,
thereby buffering the kidney from the adverse effects of reduced
arterial flow. However, a persistent reduction in systemic blood
pressure during progressive arterial stenosis ultimately will elim-
inate critical blood flow and lead to permanent loss of renal
function. Of course, this can go undetected because in patients
with a normal contralateral kidney, the non-stenotic kidney
provides adequate filtration.
DR. HARRINGTON: First, is there a modern decision analysis of
this issue? Second, you referred to some studies that you’re
interested in doing looking at the factors that might cause fibrosis
within the ischemic kidney. Which factors do you plan to look at,
and which cytokine blockers might you employ?
DR. TEXTOR: That is an interesting area for application of
formal decision analysis. In fact, Rimmer and his colleagues,
including Dr. Madias, already have published one [86]. I was
struck by the sensitivity of this analysis to the prevalence of
disease in the population treated. However, one must caution that
the assumptions underlying formal decision analysis schemes are
limited by the fact that risk and benefits of various interventions
are not distributed uniformly. Some patients are both at higher
risk for disease complications and more likely to receive interven-
tion than are others. I see no way of avoiding individualizing
therapy for each patient, given the variables involved.
Regarding your second question, our group believes that un-
derperfusion of the kidney likely activates several mechanisms
that result in interstitial fibrosis. Our hypothesis is that activation
of transforming growth factor-b (TGF-b), perhaps via local
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production of angiotensin II and disturbed endothelial function, is
a likely pathway.
DR. PERRONE: Eric Cohen speculated that there was increased
development of renal cysts in ischemic kidneys [87]. Do you have
any impressions or data about that?
DR. TEXTOR: I’m not aware of how this observation is manifest
in patients with renal arterial stenosis.
DR. B. V. R. MURTHY (Fellow, Division of Nephrology, New
England Medical Center): You had a cut-off of 1994 in your
analysis, because you didn’t want managed care to influence your
model. Did you find or expect to find any influence of managed
care in the overall managment of renovascular hypertension?
DR. TEXTOR: I did not discuss another important element,
namely, the costs of renal revascularization, reflected by hospital
stay, intensive care, surgical costs, etc. You know as well as I do
that hospital stays have shortened in recent years with the advent
of both managed care and extensive cost-control efforts. Until
now, I have had no reason to think that managed care per se has
affected our practice much in this regard. Of course, it might in
the future.
Reprint requests to Dr. S. Textor, Mayo Clinic, 200 First Street SW,
Rochester, Minnesota 55905, USA
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